Tianjin TEDA Biomedical Engineering Company Limited (HKG:8189)
Hong Kong · Delayed Price · Currency is HKD 0.3100
0.00 (0.00%)
At close: Feb 13, 2026
HKG:8189 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 400.32 | 385.48 | 398 | 403.73 | 476.38 | 369.36 | |
Revenue Growth (YoY) | -4.08% | -3.15% | -1.42% | -15.25% | 28.98% | 2.96% |
Cost of Revenue | 381.65 | 368.51 | 376.63 | 388.91 | 430.78 | 328.96 |
Gross Profit | 18.67 | 16.97 | 21.37 | 14.82 | 45.6 | 40.39 |
Selling, General & Admin | 39.16 | 34.26 | 29.91 | 33.21 | 48.76 | 40.33 |
Research & Development | 1.1 | 1.1 | 1.32 | 1.14 | 3.5 | 5.52 |
Operating Expenses | 50.25 | 45.35 | 40.7 | 39.24 | 63.99 | 65.96 |
Operating Income | -31.58 | -28.38 | -19.34 | -24.41 | -18.39 | -25.57 |
Interest Expense | -4.58 | -4.58 | -5.17 | -6.4 | -5.47 | -1.64 |
Interest & Investment Income | 0.05 | 0.05 | 0.25 | 0.76 | 0.43 | 0.83 |
Earnings From Equity Investments | - | - | - | - | 1 | -1.94 |
Currency Exchange Gain (Loss) | - | - | - | - | 0.08 | 0.17 |
Other Non Operating Income (Expenses) | -2.31 | -2.6 | -2 | 0.09 | -0.38 | -11.24 |
EBT Excluding Unusual Items | -38.42 | -35.52 | -26.26 | -29.97 | -22.73 | -39.38 |
Impairment of Goodwill | - | - | - | - | -0.42 | -7.98 |
Gain (Loss) on Sale of Investments | - | - | 0 | 5.96 | - | -1.07 |
Gain (Loss) on Sale of Assets | -0.28 | -0.28 | -0.2 | -0.05 | 0.15 | 0.24 |
Asset Writedown | -2.41 | -2.41 | - | - | -21.84 | -1.57 |
Other Unusual Items | - | - | 14.44 | - | - | -0.23 |
Pretax Income | -41.11 | -38.21 | -12.01 | -24.06 | -44.84 | -50 |
Income Tax Expense | -0.22 | -0.22 | -1.04 | -0.51 | -0.05 | 0.36 |
Earnings From Continuing Operations | -40.89 | -37.99 | -10.97 | -23.55 | -44.78 | -50.36 |
Earnings From Discontinued Operations | 1.85 | 1.85 | -5.6 | -2.44 | - | - |
Net Income to Company | -39.04 | -36.14 | -16.57 | -25.99 | -44.78 | -50.36 |
Minority Interest in Earnings | 8.94 | 8.34 | -3.59 | -1.46 | 2.53 | 2.36 |
Net Income | -30.11 | -27.8 | -20.16 | -27.45 | -42.26 | -48 |
Net Income to Common | -30.11 | -27.8 | -20.16 | -27.45 | -42.26 | -48 |
Shares Outstanding (Basic) | 1,959 | 1,895 | 1,895 | 1,895 | 1,895 | 1,895 |
Shares Outstanding (Diluted) | 1,959 | 1,895 | 1,895 | 1,895 | 1,895 | 1,895 |
Shares Change (YoY) | 3.43% | - | - | - | - | - |
EPS (Basic) | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 |
EPS (Diluted) | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 |
Free Cash Flow | -135.36 | -28.83 | -15.62 | -21.62 | -34.28 | 29.87 |
Free Cash Flow Per Share | -0.07 | -0.01 | -0.01 | -0.01 | -0.02 | 0.02 |
Gross Margin | 4.67% | 4.40% | 5.37% | 3.67% | 9.57% | 10.94% |
Operating Margin | -7.89% | -7.36% | -4.86% | -6.05% | -3.86% | -6.92% |
Profit Margin | -7.52% | -7.21% | -5.07% | -6.80% | -8.87% | -13.00% |
Free Cash Flow Margin | -33.81% | -7.48% | -3.92% | -5.36% | -7.20% | 8.09% |
EBITDA | -25.56 | -21.41 | -10.45 | -14.82 | -14.27 | -21.52 |
EBITDA Margin | -6.39% | -5.55% | -2.63% | -3.67% | -3.00% | -5.83% |
D&A For EBITDA | 6.02 | 6.97 | 8.89 | 9.59 | 4.12 | 4.05 |
EBIT | -31.58 | -28.38 | -19.34 | -24.41 | -18.39 | -25.57 |
EBIT Margin | -7.89% | -7.36% | -4.86% | -6.05% | -3.86% | -6.92% |
Advertising Expenses | - | 1.2 | 0.57 | 1.02 | 2.52 | 1.61 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.